Loading...
•
Sep 30, 2021
Nevro Q3 2021 Earnings Report
Nevro's third quarter results were reported, with revenue impacted by COVID-related issues but showing steady improvement in trial and permanent implant procedures.
Key Takeaways
Nevro reported a 14% decrease in worldwide revenue compared to the prior year, totaling $93.2 million. The company's net loss from operations was $46.4 million, which includes a $20 million patent litigation judgement. However, the company is optimistic about future growth, especially with the recent FDA approval for PDN treatment.
Received FDA Approval for 10 kHz High Frequency Spinal Cord Stimulation Therapy for Painful Diabetic Neuropathy (PDN).
Worldwide revenue was $93.2 million, a 14% decrease compared to the prior year.
Net loss from operations was $46.4 million, including a $20 million patent litigation judgement.
Provided fourth quarter revenue guidance of $94 million to $98 million.
Forward Guidance
Nevro expects fourth quarter worldwide revenue of approximately $94 million to $98 million, which includes revenue contribution from PDN. Non-GAAP adjusted EBITDA is expected to be approximately negative $10 million to negative $13 million.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...